Introducing Eric d’Esparbes, Chief Financial Officer

Today, Antheia is pleased to announce the appointment of pharma and biotech finance veteran Eric d’Esparbes as Chief Financial Officer. Ahead of today’s announcement, we sat down with Eric to learn more about his career journey, what inspired him to join Antheia’s mission, and what he’ll focus on in this new role: Tell us about […]
Biosynthetic Methods in Pharmaceutical Manufacturing

Synthetic biology advances enable engineered biosynthetic pathways, gene networks, and artificial cells, revolutionizing drug production and personalized therapies.
Rising Leaders 2025: How Christina Smolke Turned Research Into Real World Impact

The Stanford professor-turned-CEO’s 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.
Phlow Corp. Partners with Antheia to Strengthen U.S. Medicine Supply Chains

Phlow Corp. and Antheia have partnered to onshore the production of essential medicine components in the U.S.
Phlow, Antheia advance domestic production of key pharma ingredients

The partnership uses biomanufacturing and flow chemistry to onshore U.S. supplies of critical medicines.
Future of Pharma Insights: Q&A with Antheia and Phlow

We sat down with Dr. Kristy Hawkins, Co-Founder and Chief Scientific Officer at Antheia and Dr. Andrew Carpenter, Chief Scientific Officer at Phlow Corp. to discuss the new partnership, the current state of pharmaceutical manufacturing, and what the future holds for American medicine production.
Biotech Antheia is brewing cheaper Narcan, other pharmaceuticals in the U.S.

Roughly 80% of pharmaceutical ingredients rely on overseas producers. One kink in the supply chain can translate into drug shortages and critical medicines not getting to patients.
Antheia Raises $56 Million in Series C Financing to Fuel Global Commercialization Strategy
New funding will support the company’s rapid growth trajectory and efforts to transform pharmaceutical supply chains with its advanced biomanufacturing platform.
Celebrating Antheia’s Series C Financing
After a busy year marked by major commercial milestones for Antheia, we are excited to announce $56 million in Series C financing. With the support of new and existing investors, we are entering a new chapter as a business, bringing us closer than ever to a world without essential medicine shortages.
Out-Innovating Our Strategic Competitors

A conversation with John Crowley, CEO, BIO, Dr. Christina Smolke, CEO, Antheia, and Dr. Jason Roos, Acting Director, ARPA-H, moderated by Dr. Kavita Berger, Director Life Sciences Board, NAS.